CS
GENE

Credit Suisse’s Genetic Technologies Ltd. GENE Stock Holding History

Credit Suisse’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,000
Closed -$49K – 4439
2022
Q1 		$49K Buy
+5,000
New +$48.6K ﹤0.01% 3517
2021
Q1 		– Sell
-4,167
Closed -$75K – 4631
2020
Q4 		$75K Buy
+4,167
New +$68.8K ﹤0.01% 4209

Other funds holding GENE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Credit Suisse's GENE Position: Q2 2022 in Review

Credit Suisse sold out of Genetic Technologies Ltd. (GENE) in Q2 2022, closing a stake of 5,000 shares — an estimated $49K sold.

Credit Suisse first reported a position in GENE in Q4 2020 and held it in 2 quarters. The position peaked at $75K in Q4 2020. 12 funds tracked by Wall St. Rank hold GENE as of Q2 2022.

  • Credit Suisse reported no remaining Genetic Technologies Ltd. position as of Q2 2022 after selling out during the quarter.
  • Credit Suisse sold 5,000 Genetic Technologies Ltd. shares in Q2 2022, an estimated $49K.
  • Credit Suisse first reported a position in Genetic Technologies Ltd. in Q4 2020 and held it in 2 quarters.
  • Credit Suisse's Genetic Technologies Ltd. position peaked at $75K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q2 2022.

Based on Credit Suisse's 13F filing for Q2 2022, filed 12 Aug 2022.